Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the ...
Viking Therapeutics starts Phase 1 study on novel weight loss drug in healthy adults: San Diego Thursday, June 25, 2026, 18:00 Hrs [IST] Viking Therapeutics, Inc., a clinical-stag ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase I study ...
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss ...
Shares of Viking Therapeutics VKTX rose about 9% on Wednesday after the company expanded its obesity pipeline by advancing a ...
Viking Therapeutics Inc. VKTX announced on Wednesday that it has initiated a Phase 1 trial evaluating VK3019, an ...
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) ...
The Hearty Soul on MSN
New diabetes treatment may replace insulin injections with sweet treat
A new oral insulin embedded in sugar-free chocolate uses nano-carriers to target the liver, cutting hypoglycemia risk. The ...
MedPage Today on MSN
FDA Scientists Raise Peptide Concerns Ahead of Committee Meeting
RFK Jr. recently added peptide-friendly members to a key panel ...
Detailed price information for Elicio Therapeutics Inc (ELTX-Q) from The Globe and Mail including charting and trades.
Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer’s disease (AD) research, including lecanem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results